Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing...
-Â With a proven track record at Entrada and across his 30-year career in the healthcare sector, Mr. Dowden is well-positioned to help continue driving Entrada™s operational growth - BOSTON, Jan. 03,...
“ Company completes dosing of first and second cohorts in Phase 1 clinical trial, ENTR-601-44-101 “ “ ENTR-601-44 clinical development program remains on track with data readout expected in second...
Despite Entrada Therapeutics' efforts to persuade the FDA with additional information, the regulatory agency has rejected the company's attempts to lift the nearly yearlong clinical hold on its leading Duchenne muscular dystrophy (DMD) candidate.
Initiated a Phase 1 clinical trial of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy, marking Entrada™s transition to a clinical-stage company Expanded the Company™s...
BOSTON, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing...
“ Initiation of Phase 1 clinical trial marks Entrada™s transition into a clinical company “ “ Data anticipated in the second half of 2024 “ BOSTON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Entrada...
- In its inaugural year, DREAMS Grant Program awards $25,000 each to three U.S.-based non-profit organizations working to combat disparity and support people living with Duchenne - - Announced in...
BOSTON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal...